New Search

If you are not happy with the results below please do another search

2034 search results for:

112

Bruker acquires ZONTAL to advance the digital lab transformation

Bruker Corporation has acquired ZONTAL, an innovative platform provider for the digital transformation of the analytical laboratory, and for integrated biopharma technical data solutions. This acquisition further strengthens Bruker BioSpin’s Integrated Data Solutions (IDS) software division, which includes Mestrelab Research (www.mestrelab.com), Arxspan (www.arxspan.com) and Optimal (www.optimal-ltd.co.uk).

113

Oxford Nanopore, bioMérieux partner to develop infectious disease diagnostics

Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux, a world leader in the field of in vitro diagnostics, are teaming up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

114

Maxion Therapeutics awarded £2M Innovate UK funding to develop ion channel antibodies to treat autoimmune diseases

Biotechnology company Maxion Therapeutics has been awarded a £2 million grant from Innovate UK, as part of its Biomedical Catalyst 2022 Round 2: Industry-led R&D funding competition. The funds will support the use of Maxion’s proprietary KnotBody platform www.maxiontherapeutics.com/#technology to develop antibodies to treat autoimmune diseases (AID) with high unmet clinical need.

115

Thermo Fisher Scientific, Pfizer collaborate to expand accesss to next-generation sequencing-based cancer testing in more than 30 countries

Pfizer and Thermo Fisher Scientific have agreed to collaborate to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can […]

116

Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors. The announcement follows a series of appointments to the Company’s senior leadership team, as part of its ambitious global growth strategy.

118

Certest Biotec

Certest Biotec, the University of Zaragoza and the University of the Basque Country are working on developing a new inhaled vaccine against tuberculosis, as a reinforcement of the current and future vaccines.

119

Scientists identify new biomarker that may predict treatment response to chemoimmunotherapy

Scientists identify new biomarker that may predict treatment response to chemoimmunotherapy Cutting-edge cancer treatments like immunotherapy are offering new hope for patients, often in combination with more common approaches such as chemotherapy. But determining the best treatment combination isn’t always straightforward. Many patients spend valuable time on expensive therapies with serious side effects that aren’t […]